Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.

被引：0
|
作者：
Maraka, Stefania
Groves, Morris D.
Mammoser, Aaron Gerald
Melguizo-Gavilanes, Isaac
Conrad, Charles A.
Tremont-Lukats, Ivo
Loghin, Monica Elena
O'Brien, Barbara Jane
Puduvalli, Vinay K.
Sulman, Erik P.
Hess, Kenneth R.
Aldape, Kenneth D.
Gilbert, Mark R.
De Groot, John Frederick
Yung, W. K. Alfred
Penas-Prado, Marta
机构：
[1] Univ Texas MD Anderson Canc Ctr, Neurooncol Dept, Houston, TX USA
[2] LSU Hlth Sci Ctr, Dept Neurosurg, New Orleans, LA USA
[3] Aurora Canc Care Neurooncol, Milwaukee, WI USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Houston Methodist Hosp, Neurooncol, Neurol, Houston, TX USA
[6] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[7] Natl Canc Inst, Ctr Canc Res, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2044
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
    Prados, Michael D.
    Chang, Susan M.
    Butowski, Nicholas
    DeBoer, Rebecca
    Parvataneni, Rupa
    Carliner, Hannah
    Kabuubi, Paul
    Ayers-Ringler, Jennifer
    Rabbitt, Jane
    Page, Margaretta
    Fedoroff, Anne
    Sneed, Penny K.
    Berger, Mitchel S.
    McDermott, Michael W.
    Parsa, Andrew T.
    Vandenberg, Scott
    James, C. David
    Lamborn, Kathleen R.
    Stokoe, David
    Haas-Kogan, Daphne A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 579 - 584
  • [32] Phase I/Pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed Glioblastoma Multiforme (GBM) or Gliosarcoma (GS)
    Butowski, Nicholas
    Lamborn, Kathleen
    Chang, Susan
    DeBoer, Rebecca
    Page, Margaretta
    Rabbitt, Jane
    Fedoroff, Ann
    Parvataneni, Rupa
    Kivett, Valene
    Nicol, Steuen J.
    Musib, Luna
    Leipa, Astra
    Thornton, Donald
    Prados, Michael
    NEUROLOGY, 2008, 70 (11) : A295 - A296
  • [33] Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
    Wen, Patrick Yung
    Rodon, Jordi A.
    Mason, Warren
    Beck, Joseph T.
    DeGroot, John
    Donnet, Valerie
    Mills, David
    El-Hashimy, Mona
    Rosenthal, Mark
    ESMO OPEN, 2020, 5 (04)
  • [34] PHASE I STUDY OF RUXOLITINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS AND GLIOBLASTOMA
    Rauf, Yasmeen
    Hufsey, Rachel
    Robinson, Kathy
    Suh, John
    Chao, Samuel
    Murphy, Erin
    Yu, Jennifer
    Peereboom, David
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2021, 23 : 69 - 69
  • [35] PHASE I STUDY OF RUXOLITINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS AND GLIOBLASTOMA
    Rauf, Yasmeen
    Hufsey, Rachel
    Robinson, Kathy
    Suh, John
    Chao, Samuel
    Murphy, Erin
    Yu, Jennifer
    Peereboom, David
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2020, 22 : 51 - 51
  • [36] Randomized Phase II trial of Tumor Treating Fields plus radiation therapy plus temozolamide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma
    Grossman, Rachel
    Limon, Dror
    Bokstein, Felix
    Ben Harosh, Carmit
    Ram, Zvi
    CANCER RESEARCH, 2019, 79 (13)
  • [37] NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL® FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY
    Desjardins, Annick
    Peters, Katherine B.
    Herndon, James E., II
    Bailey, Leigh Ann
    Alderson, Lloyd M.
    Ranjan, Tulika
    Sampson, John H.
    Friedman, Allan H.
    Bigner, Darell D.
    Friedman, Henry S.
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2012, 14 : 104 - 104
  • [38] Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Butowski, Nicholas
    Chang, Susan M.
    Lamborn, Kathleen R.
    Polley, Mei-Yin
    Pieper, Russell
    Costello, Joseph F.
    Vandenberg, Scott
    Parvataneni, Rupa
    Nicole, Angelina
    Sneed, Patricia K.
    Clarke, Jennifer
    Hsieh, Emily
    Costa, Bruno M.
    Reis, Rui M.
    Hristova-Kazmierski, Maria
    Nicol, Steven J.
    Thornton, Donald E.
    Prados, Michael D.
    NEURO-ONCOLOGY, 2011, 13 (12) : 1331 - 1338
  • [39] A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
    Rosenfeld, M. R.
    Chamberlain, M. C.
    Grossman, S. A.
    Peereboom, D. M.
    Lesser, G. J.
    Batchelor, T. T.
    Desideri, S.
    Salazar, A. M.
    Ye, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase I/pharmacokinetic (PK) study of enzastaurin plus temozolomide during and following radiation therapy in patients (PTS) with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
    Butowski, Nicholas
    Lamborn, Kathleen
    Chang, Susan
    DeBoer, Rebecca
    Page, Margaretta
    Rabbitt, Jane
    Fedoroff, Anne
    Parvataneni, Rupa
    Kivett, Valerie
    Nicol, Steven
    Musib, Luna
    Liepa, Astra
    Thornton, Donald E.
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 515 - 515
12345